SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ARIAD Pharmaceuticals
ARIA 23.990.0%Feb 17 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: tejek11/2/2013 12:27:36 AM
   of 4474
 
Noted on the IHUB Biotech Values site.............an important data point from the article that I believe was filed with the NEJM:

There were 10 CP patients at 2mg, 4mg, 8mg, 15mg doses, 3 with T315I, 7 with non-T315I mutations, MCyR was 7/10=70%, 3/3=100%, 4/7=57% respectively.

ariad.com

That means there was still efficacy with doses at or lower than 15mg especially for the T315I mutation.


Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News